Interpace Diagnostics Group (NASDAQ:IDXG) Given a $3.00 Price Target at HC Wainwright

HC Wainwright set a $3.00 price objective on Interpace Diagnostics Group (NASDAQ:IDXG) in a research note issued to investors on Friday, July 27th. The brokerage currently has a buy rating on the business services provider’s stock.

Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of Interpace Diagnostics Group from a hold rating to a buy rating and set a $1.00 price target on the stock in a report on Wednesday, May 9th. Maxim Group restated a buy rating and issued a $3.00 price target on shares of Interpace Diagnostics Group in a report on Wednesday, May 30th. LADENBURG THALM/SH SH began coverage on shares of Interpace Diagnostics Group in a report on Friday, June 22nd. They issued a buy rating and a $2.25 price target on the stock. Finally, ValuEngine upgraded shares of Interpace Diagnostics Group from a sell rating to a hold rating in a research note on Saturday, June 2nd. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $2.75.

NASDAQ IDXG traded up $0.04 during trading on Friday, reaching $1.07. 1,333,456 shares of the company’s stock traded hands, compared to its average volume of 556,876. Interpace Diagnostics Group has a 12-month low of $0.72 and a 12-month high of $1.80.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings results on Thursday, August 9th. The business services provider reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. Interpace Diagnostics Group had a negative net margin of 71.14% and a negative return on equity of 34.55%. The business had revenue of $5.50 million for the quarter, compared to analysts’ expectations of $4.80 million. equities research analysts expect that Interpace Diagnostics Group will post -0.37 EPS for the current year.

Interpace Diagnostics Group Company Profile

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

See Also: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with's FREE daily email newsletter.

Leave a Reply